

GCT-44. A CASE OF INTRACRANIAL GERMINOMA WHICH RECURRENT IN THE SPINAL CORD 13 YEARS AFTER THE INITIAL TREATMENT

Yasuhiro Murota, Juri Kiyokawa, Mariko Ishikawa, Hiroto Yamaoka, Satoshi Kaneko, Masataka Yoshimura, Shin Hirota, and Shinji Yamamoto; Tsuchiura Kyodo General Hospital, Tsuchiura, Ibaraki, Japan

BACKGROUND: Central nervous system germinoma occurs most often in early teens, accounting for 15% of childhood brain tumors. Here, we report a case of germinoma which recurred in the spinal cord 13 years after complete remission. **CASE DESCRIPTION:** A 15-year-old boy presented with diabetes insipidus (DI). MRI showed a pineal gland tumor and ventriculomegaly. Biopsy was performed and the histological examinations revealed PLAP and c-kit positive pure germinoma. Ki67 LI was 64.4%. Gamma knife radiosurgery and 3 courses of ICE chemotherapy brought disappearance of the tumor. However, it recurred in lateral ventricles. Forty-Gray whole brain radiation resulted in complete remission of the tumor. For the sake of DI treatment and MRI examinations, he kept periodical visit to our hospital. Thirteen years later, when he was 28y/o, he complained paresthesia in the right upper extremity. MRI demonstrated gadolinium-enhance mass lesion in the cervical spinal cord. Recurrence of the tumor and multiple sclerosis were the principal differential diagnosis. Pulse steroid therapy did not make any change, and radiation therapy to the cervical spinal cord led to tumor disappearance. Nevertheless, the tumor recurred on the dorsal medulla oblongata one and a half years later. Biopsy of the tumor clarified that the tumor was germinoma. ICE chemotherapy which was limited to three courses due to severe bone marrow suppression was carried out. MRI proved no enhanced mass lesion in the central nervous system. **DISCUSSION:** Germinoma may recur even after long period of remission, demonstrating that long-term follow-up is indispensable.

GCT-45. YOLK SAC TUMOR IN THE CEREBELLAR VERMIS - A CASE REPORT

Saori Otake¹, Tomoo Matsutani¹, Yousuke Watanabe¹, Osamu Numata², Ryo Ando², Hidemasa Ochiai³, Ikeda Junichiro⁴, and Yasuo Iwadate¹; ¹Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba, Japan. ²Department of Neurosurgery, Chiba Child Hospital, Chiba, Japan. ³Department of Hematology and Oncology, Chiba Child Hospital, Chiba, Japan. ⁴Department of Pathology, Chiba University Graduate School of Medicine, Chiba, Japan

Yolk sac tumor (YST) is a non-germinomatous malignant germ cell tumor in a young child. It usually arises along a midline axis, mostly pineal region or suprasellar compartment, and it is exceedingly rare to locate in a cerebellar vermis. In the present report, we describe a case of a pure YST located in the cerebellar vermis and review the previous literature. A three-year-old boy visited a local clinic for gait disturbance and frequent vomiting. Gadolinium-enhanced magnetic resonance imaging (MRI) showed a homogeneously-enhanced mass with a cystic component in his cerebellar vermis, and it resulted in hydrocephalus. By its location and his age, our pre-operative diagnosis was a medulloblastoma, and we performed a total resection of the tumor with ventricular drainage. Unexpectedly, the histological investigation revealed it to be a YST. We confirmed that the serum levels of α -fetoprotein (AFP) had elevated at 3176.4 ng/ml in his preserved sample, obtained before the surgery, and it was consistent with the pathological diagnosis. He is receiving chemotherapy consisting of ifosfamide, cisplatin, and etoposide, followed by radiation therapy. In this case, pre-operative MRI revealed that the tumor did not grow into the IVth ventricle in spite of midline location, which was not typical for medulloblastoma. Of note, serum AFP levels had increased, and they might contribute to a precise pre-operative diagnosis and be able to propose an alternative treatment plan, such as neoadjuvant chemotherapy to reduce surgical risk. As a conclusion, a YST should be considered even if it locates in a cerebellar vermis.

GCT-46. MULTI-KINASE INHIBITORS AS NOVEL THERAPEUTIC AGENTS AGAINST INTRACRANIAL NON-GERMINOMATOUS GERM CELL TUMORS

Eita Uchida^{1,2}, Tatsuya Ozawa¹, Masamichi Takahashi³, Ryo Nishikawa², Koichi Ichimura¹, and Arata Tomiyama^{1,4}; ¹National Cancer Center Research Institute, Chuo-Ku, Tokyo, Japan, ²Saitama Medical University International Medical Center, Hidaka, Saitama, Japan, ³National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan, ⁴National Defense Medical College, Tokorozawa, Saitama, Japan

Central nervous system germ cell tumors (CNS GCTs) are rare intracranial malignancies developing in adolescents and young adults which relatively frequently occur in East Asia region of the world including Japan. However, among CNS GCTs, non-germinomatous germ cell tumors (NGGCTs) are highly resistant to the current chemoradiotherapies, and the prognosis of CNS NGGCTs is still extremely poor. Therefore, development of novel therapeutic strategy against CNS NGGCTs is urgently needed. In this study,

we screened small molecule inhibitors of kinases specifically targeting cell membrane receptors, such as receptor tyrosine kinases, and their related molecular signaling, which could effectively exert antitumor effects against NGGCT cells. As the NGGCT model cells, the Tcam2 cell, a mixed germ cell tumor cell line composed of germinoma and embryonal carcinoma components, and the YST1 cell, a novel yolk sac tumor cell line established in our institute, were used. As a result, effective induction of cell death in both cell lines was confirmed only by treatment with two multi-kinase inhibitors. Immunoblotting revealed these multi-kinase inhibitors suppressed activation of various kinases concurrently. Furthermore, these multi-kinase inhibitors also triggered cell death in the Tcam2 cell stably expressing mutant KIT, the most common oncogenic driver genes of CNS GCTs, suggesting that these inhibitors would be also effective against CNS GCTs harboring activated KIT mutants. In vivo studies of these multi-kinase inhibitors using CNS GCT xenografts are currently on going.

GCT-47. TREATMENT STRATEGIES FOR GIANT IMMATURE TERATOMAS IN INFANTS

Tomoru Miwa¹, Maya Kono¹, Haruko Shima², Hiroyuki Shimada², and Kazunari Yoshida¹; ¹Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan. ²Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan

INTRODUCTION: Immature teratomas are the most frequent fetal brain tumors and show a poor prognosis. At onset, the tumor is often al-ready giant with deep origins such as suprasellar or pineal region, and easy bleeding is also considered to be a cause of poor prognosis. On the other hand, it is also known that the prognosis is improved in total removal cases. **METHODS:** We investigated the best treatment strategy based on two cases of total removal of giant immature teratomas in infants. **RESULTS:** 1.5 month after birth at onset (median), maximum diameter of 75 mm (median). A giant tumor centered around the third ventricle with hydrocephalus. First, biopsy (+septostomy) was performed using an endoscope. The tumor showed easily bleeding. In addition, external ventricular drainage was taken out of the lower abdomen subcutaneously by long tract. After chemotherapy (carboplatin and etoposide), tumor removal was performed by using drainage tract. Both cases showed not easily bleeding at that time and the tumor was safely removed. Regarding the deep blind spot, using a flexible endoscope was effective. They showed no recurrence after total removal (median 50 months). **DISCUSSION:** There have been reports of cases in which chemotherapy for immature teratomas suppressed tumor growth and reduced bleeding and safely removed totally. In infants giant immature teratomas, chemotherapy before tumor removal can be expected to reduce bleeding, and further increase body weight during that period. In addition, long-term placement of ventricular drainage by long tract during the chemotherapy can prevent brain development delay due to hydrocephalus.

GCT-48. OUTCOME OF CNS MALIGNANT NON-GERMINOMATOUS GERM CELL TUMORS (GCT) WITH AFP > 1000 NG/ML AT DIAGNOSIS TREATED ACCORDING TO SIOP CNS GCT 96

Gabriele Calaminus¹, Didier Frappaz², Rolf-Dieter Kortmann^{3,4}, Thankamma Ajithkumar⁴, Torsten Pietsch⁵, Alexandre Vasiljevic⁶, Umberto Ricardi⁷, Cecile Faure-Conte⁸, Beate Timmermann⁹, Claire Alapetite¹⁰, Matthew J Murray¹¹, Maria Luisa Garre¹², and James C Nicholson¹¹; ¹Department of Paediatric Haematology and Oncology University Hospital, Bonn, Germany, ²Department of Paediatric Haematology and Oncology, Institute of Paediatric Haematology and Oncology (IHOPe), Lyon, France, ³Department of Radiotherapy and Radiooncology, University Hospital, Leipzig, Germany, ⁴Department of Radiotherapy and Radiooncology, University Hospital, Cambridge, United Kingdom, ⁵Institute of Neuropathology, University of Bonn Medical Center, Bonn, Germany, ⁶Department of Biopathology, Institut Multisite de Pathologie, Hospices Civiles, Lyon, France, ⁷Department of Oncology, University of Turin, Turin, Italy, ⁸Department of Paediatric Haematology and Oncology, Institute of Paediatric Haematology and Oncology (IHOPe), Lyon, France, ⁹Department of Radiation Oncology, Clinic of Proton Therapy, Essen, Germany, ¹⁰Department of Radiation Oncology, Curie Institute, Paris, France, ¹¹Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ¹²Department of Paediatric Haematology and Oncology, Gaslini Childrens Hospital, Genova, Italy

Analysis of CNS MMGCT with AFP >1000 ng/ml (serum and/or CSF) at diagnosis, treated on trial in SIOP-CNS-GCT-96, revealed an inferior prognosis (32% 5-year progression-free survival) compared with AFP <1000 ng/ml (76%). As this patient group is small, to evaluate a bigger cohort, we revisited all patients treated according to SIOP-CNS-GCT-96, who were registered in the database until July 2015. Between October 1996 and July 2015, 373 patients with CNS MMGCT were registered. 48 patients (13%)